Contents

List of Contributors xxvi

Preface xxxvii

1 $_3$Li Lithium Metallotherapeutics 1
Robin S.B. Williams and Adrian J. Harwood

1.1 Introduction 1

1.2 The Inorganic Chemistry of Lithium 2

1.3 Biology of Lithium 3
1.3.1 The history of lithium therapeutics 3
1.3.2 Lithium and the body 4

1.4 Targets of Lithium 5
1.4.1 Glycogen synthase kinase-3 5
1.4.2 Inositol phosphate signalling 8

1.5 Lithium Therapeutics 10
1.5.1 Bipolar disorder and schizophrenia 10
1.5.2 Alzheimer's disease 12
1.5.3 Ischemia (stroke) 14
1.5.4 Adverse effects 14

Acknowledgements 15

References 15

2 $_5$B Boron Compounds as Therapeutic Drugs 19
Geeta Rana, Kamesh Vyakaranam, John A. Maguire and Narayan S. Hosmane

2.1 Boron Neutron Capture Therapy 19

2.2 Classes of Boron Compounds for Potential Use in BNCT 22
2.2.1 DNA binders 22
2.2.2 Boron-containing amino acids and related peptides 24
2.2.3 Boron-containing nucleic acid precursors 27

2.3 Phosphates, Phosphonates and Phosphoramidates 31

2.4 Amines 33

2.5 Boron Analogues of Pyrophosphates 33

2.6 Boronated Polyamines 34

2.7 Carbohydrates 36

2.8 Lipoproteins 36

2.9 Lipids and Phospholipids 37

2.10 Radiation Sensitizers 38

2.11 Cyclic Thiourea Derivatives 38

2.12 Central Nervous System (CNS) Depressants: Promazines, Hydantoins and Barbiturates 39

2.13 Hydantoins and Barbiturates 39

2.14 Oligonucleotide Antisense Agents 40

2.15 Hormones 42

2.16 Liposomes 44

2.17 Conclusions 45

Acknowledgements 46

References 46

3 $_{12}$Mg The Role of Magnesium as a Metallotherapeutic Drug 51
Pietro Delva

3.1 Introduction 51

3.2 Magnesium as a Drug 53
3.2.1 Gestational hypertension, preeclampsia and eclampsia 53
3.2.2 Asthma 54
3.2.3 Stroke 55
3.2.4 Acute myocardial infarction 57
3.2.5 Arrhythmias 60
3.2.6 Miscellaneous 61

References 62

4 $_{13}$Al Aluminum Metallotherapeutics 65
Thanos Salifoglou

4.1 Introduction 65

4.2 Adjuvants 66
4.2.1 Alum 66
4.2.2 $Al(OH)_3$ 67
4.2.3 Aluminum phosphate 69

4.3 Antacids 69
4.3.1 Aluminum hydroxide 69
4.3.2 Aluminum glycinate 70
4.3.3 Peptic ulcer disease 70
4.3.4 Bismuth aluminum carbonate 73
4.3.5 Bismuth–magnesium–sodium alumino-silicate 73

4.4 Phosphate Binders 73
4.4.1 Basic aluminum carbonate 75
4.4.2 Alumino-silicates 75

4.5 Alginate Raft Formulations 75
4.6 Blistering Diseases in the Elderly 77
4.7 Metabolic Diseases and Aluminum 77
4.8 Anti-malarial Substances 78
4.9 Potential Aluminum Toxicity 79
4.10 Conclusions 80
References 80

5 $_{14}$Si Biological Activity of Organosilicon Compounds 83
Edmunds Lukevics and Luba Ignatovich
5.1 Introduction 83
5.2 Organosilicon Modification 84
5.2.1 O-, S- and N-Silylation 84
5.2.2 C-Silylation 89
5.3 Sila Analogues 92
5.4 Specific Organosilicon Compounds 94
References 96

6 $_{20}$Ca The Role of Calcium as a Metallotherapeutic Drug 109
Mario Barbagallo and Ligia J. Dominguez
6.1 Introduction 109
6.2 Calcium Homeostasis 110
6.3 Hormonal Regulation of Calcium Metabolism 111
6.4 Optimal Amount of Dietary Calcium Intake and Benefits of Calcium Supplementation 112

6.5 Osteoporosis 115
6.6 Hypertension 116
6.7 Hypertension in Pregnancy and Preeclampsia 118
6.8 Colon Cancer 119
6.9 Weight Control and Regulation of Body Fat 119
6.10 Periodontal Disease 120
6.11 Kidney Stones 121
6.12 Calcium Supplements: Side Effects 121
6.13 Conclusions 122
References 123

7 $_{22}$Ti Anti-tumor Titanium Drugs 125
Erich Dubler
7.1 Introduction 125
7.2 The Biochemistry of Titanium 126
7.3 Titanium Anti-cancer Drugs 127
7.4 Budotitane 130
7.4.1 Chemistry and anti-cancer activity 130
7.4.2 Isomer abundance of budotitane 131
7.4.3 Reaction with biomolecules 133
7.4.4 Animal studies 134
7.4.5 Clinical investigations 134
7.5 Titanocene Dichloride 135
7.5.1 Chemistry and anti-cancer activity 135
7.5.2 Reaction with biomolecules 136
7.5.3 Animal studies 137
7.5.4 Clinical investigations 138
7.5.5 Perspectives of titanocene dichloride 138

7.6 Conclusions 139

Acknowledgements 140

References 140

8 $_{23}$V Insulin-Mimetic Vanadium-Containing Compounds 143
Tamás Kiss and Tamás Jakusch

8.1 Chemistry of Vanadium 143

8.2 Biological and Medicinal Aspects of Vanadium 144

8.3 The Role of Insulin in Glucose Metabolism 144

8.4 Vanadium Complexes with Biological Activity 145

8.5 Biological Activity and Toxicity of Various Vanadium(IV/V) Compounds 148

8.6 Speciation of VI(IV) Complexes in Biological Fluids 149

8.7 Possible Mechanism for *in vivo* Vanadium Action 153

8.8 Conclusion 155

Acknowledgements 156

References 156

9 $_{25}$Mn Manganese Metallotherapeutics 159
Jeanne H. Freeland-Graves, Tanushree Bose and Abbass Karbassian

9.1 Prevalence in the Environment 159

9.2 Diet and Water 160

9.3 Functions 160

9.4 MnSOD 160

9.5 Deficiency 161
9.5.1 Animals 161
9.5.2 Humans 162

9.6 Toxicity 162

9.7 Therapeutic Manganese-Related Agents 163

9.8 Therapeutic Uses 165
9.8.1 Arthritis 165
9.8.2 Cancer 166
9.8.3 Cardiovascular diseases 167
9.8.4 Dermatitis 168
9.8.5 Diabetes 168
9.8.6 Epilepsy 169
9.8.7 Human immunodeficiency virus 169
9.8.8 Inflammatory pain and response 170
9.8.9 Ischemia and reperfusion injury 171
9.8.10 Osteoporosis 171
9.8.11 Peritoneal adhesions 172
9.8.12 Premenstrual syndrome 172
9.8.13 Shortened life span (premature aging) 173
9.8.14 Other disorders 174

9.9 Magnetic Resonance Imaging (MRI) 174

9.10 Future Implications 175

Acknowledgements 175

References 176

10 $_{26}$Fe The Use of Iron-Based Drugs in Medicine 179
Xiang Wu and Mei Lin Go

10.1 Introduction 179

10.2 Ferrocene 180

10.3 TMH Ferrocene 181

10.4 Ferrocene in Drug Design 181
10.4.1 Examples where introduction of ferrocene has resulted in a loss or no change in activity 182
10.4.2 Examples where introduction of ferrocene has resulted in enhanced activity or a change in activity profile 183

10.5 Ferrochloroquine 185

10.6 Other Ferrocenyl Anti-plasmodial Agents 191

10.7 Organoiron as Anti-cancer Agents 193

10.8 Conclusions 197

References 198

11 $_{27}$Co Cobalt Complexes as Potential Pharmaceutical Agents 201
Hui Chao and Liang-Nian Ji

11.1 Introduction 201

11.2 Enzyme Inhibition/Induction 202
11.2.1 Serine protease inhibitors 202
11.2.2 Topoisomerase II inhibitors 202
11.2.3 Heme oxygenase-1 inducers 203

11.3 Nucleic Acid Binding and Cleavage 204
11.3.1 Cobalt(III) polypyridyl complexes 204
11.3.2 Cobalt(III) bleomycin complexes 206
11.3.3 Cobalt(III) polyamine complexes 208

11.4 Miscellaneous 209
11.4.1 Cobalamin conjugates as drug delivery devices 209
11.4.2 Hypoxic selective agents 211
11.4.3 PET imaging agents 213

11.5 Conclusions 214

Acknowledgements 214

References 214

12 $_{29}$Cu Chemotherapeutic Copper Compounds 219
Francisco González-Vílchez and Rosario Vilaplana

12.1 Introduction 219

12.2 Copper-Purine Derivatives Complexes 220

12.3 Copper-Thiosemicarbazone Complexes 223

12.4 Copper-Benzohydroxamic Acid Complexes 230

12.5 Copper-Imidazole Derivatives Complexes 230

12.6 Copper-Polycarboxylate Complexes 233

Acknowledgements 234

References 235

13 $_{30}$Zn The Role of Zinc as a Metallotherapeutic Agent 237
Jane V. Higdon and Emily Ho

13.1 Introduction 237

13.2 Functions 237
13.2.1 Catalytic functions 238
13.2.2 Structural functions 238
13.2.3 Regulatory functions 238

13.3 Zinc Deficiency 238
13.3.1 Severe zinc deficiency 239
13.3.2 Mild zinc deficiency 239
13.3.3 Growth retardation 239

13.4 **Increased Susceptibility to Infectious Disease** 240
13.4.1 Diarrhea 240
13.4.2 Pneumonia 240
13.4.3 Malaria 240

13.5 **Risk Factors for Zinc Deficiency** 241
13.5.1 Dietary factors that decrease zinc absorption 241
13.5.2 Intake recommendations 241

13.6 **Therapeutic Uses of Zinc** 243
13.6.1 Wilson disease 243
13.6.2 Age-related macular degeneration 243
13.6.3 Human immunodeficiency virus (HIV) infection 243
13.6.4 Type 1 diabetes 244
13.6.5 Wound healing 244

13.7 **Common Cold** 245
13.7.1 Oral zinc 245
13.7.2 Intranasal zinc 245

13.8 **Zinc Status and Its Relevance to Cancer** 245
13.8.1 Zinc deficiency and oxidative stress 246
13.8.2 Zinc and DNA repair 247
13.8.3 Zinc and prostate cancer 249

13.9 **Safety** 251
13.9.1 Toxicity 251
13.9.2 Drug interactions 252

13.10 **Conclusions** 252

References 252

14 **$_{31}$Ga Therapeutic Gallium Compounds** 259
Lawrence R. Bernstein

14.1 **Introduction** 259

14.2 **Chemistry and Mechanisms of Action** 260
14.2.1 Aqueous biochemistry 260

14.2.2 Gallium and iron 261
14.2.3 Mechanisms of action 264

14.3 Therapeutic Gallium Compounds 265
14.3.1 Gallium nitrate and citrated gallium nitrate 265
14.3.2 Gallium chloride 269
14.3.3 Gallium 8-quinolinolate 269
14.3.4 Gallium maltolate 270
14.3.5 Other gallium compounds 271

Abbreviations Used 273

References 273

15 $_{32}$Ge Biological Activity of Organogermanium Compounds 279
Edmunds Lukevics and Luba Ignatovich

15.1 Introduction 279

15.2 Biological Activity 282
15.2.1 2-Carboxyethylgermanium sesquioxide 282
15.2.2 Spirogermanium 285
15.2.3 Germatranes 286
15.2.4 Germanium modified organic compounds 288

References 290

16 $_{33}$As Metallotherapeutic Arsenic Compounds 297
Paul C. Ho

16.1 Introduction 297

16.2 Chemistry of Arsenic 299

16.3 Mechanisms of Action 300
16.3.1 Modulation of PML and PML–RARα genes 301
16.3.2 Induction of intracellular reactive oxygen species (ROS) 302
16.3.3 Collapse of the mitochondrial membrane potential 303

16.3.4 Roles of glutathione 303
16.3.5 Down-regulation of bcl-2 304
16.3.6 Involvement of p53 304
16.3.7 Activation of caspases 305
16.3.8 Other mechanisms of arsenic-induced apoptosis 305

16.4 Pharmacokinetic Profiles 306
16.4.1 Absorption, distribution and excretion 306
16.4.2 Metabolism 306

16.5 Toxic Side Effects of As_2O_3 307

16.6 Indications and Uses of As_2O_3 308

16.7 Summary and Conclusions 308

Acknowledgements 309

References 309

17 $_{34}Se$ The Use of Selenium-Based Drugs in Medicine 313
Michael Carland and Tahli Fenner

17.1 Introduction to Selenium and its Biochemistry 313

17.2 Diseases Associated with Selenium Deficiency 315
17.2.1 Asthma 316
17.2.2 Keshan disease 316
17.2.3 Human immunodeficiency virus (HIV) 317

17.3 Therapeutic Uses of Supranutritional Doses of Selenium 317
17.3.1 Arsenism 317
17.3.2 Cancer prevention 318

17.4 Synthetic Selenium-Containing Therapeutics 321
17.4.1 Anti-oxidants and anti-inflammatory agents 321
17.4.2 Anti-cancer 324
17.4.3 Anti-hypertensives 327
17.4.4 Anti-virals and anti-bacterials 327

17.5 Conclusion 328

References 328

18 $_{43}$Tc Technetium in Medicine 333
Oyebola O. Sogbein and John F. Valliant

18.1 Overview 333

18.2 Technetium: Historical Accounts and Properties Relevant to Nuclear Medicine 334

18.3 Technetium Radiopharmaceuticals 336
18.3.1 Tc-essential compounds 336
18.3.2 Tc-tagged compounds 338

18.4 Peptide-Targeted Radiopharmaceuticals 343

18.5 Current Areas of Research 344
18.5.1 Bioorganometallic chemistry 344
18.5.2 Tc and solid supports 345
18.5.3 Technetium-94m 349

18.6 Outlook 350

References 352

19 $_{44}$Ru Perspectives of Ruthenium Complexes in Cancer Therapy 359
Olivier Lentzen, Cécile Moucheron and Andrée Kirsch-De Mesmaeker

19.1 Introduction 359

19.2 Ruthenium Complexes that Mimic Platinum Drugs 360
19.2.1 Chloro-ammino derivatives 361
19.2.2 Dimethyl-sulfoxide complexes 362
19.2.3 Complexes with mixed chloride and heterocyclic ligands 364

19.3 **Design of New Anti-cancer Compounds based on the Photoreactivity of Polyazaaromatic Ruthenium(II) Complexes** 365
19.3.1 Energy transfer processes leading to photo-cleavages 367
19.3.2 Photoelectron transfer processes leading to DNA cleavages 368
19.3.3 Photoelectron transfer processes leading to photoadduct formation 371

19.4 **Targeting Base Residues of Specific Sequences** 373

19.5 **Conclusions** 375

References 376

20 **$_{45}$Rh Rhodium in Medicine** 379
Florian P. Pruchnik

20.1 **Introduction** 379

20.2 **Anti-tumor Activity of Rhodium Complexes** 379
20.2.1 Rhodium(I) complexes 380
20.2.2 Rhodium(II) complexes 381
20.2.3 Rhodium(III) complexes 385

20.3 **Anti-bacterial and Anti-parasitic Activity** 388

20.4 **Radiorhodium Agents** 390

20.5 **Photochemotherapy** 391

20.6 **Toxicity of Rhodium Complexes** 392

References 394

21 **$_{46}$Pd The Use of Palladium Complexes in Medicine** 399
Achilleas Garoufis, Sotiris K. Hadjikakou and Nick Hadjiliadis

21.1 **Introduction** 399

21.2 **Anti-viral, Anti-fungal and Anti-microbial Activity of Pd(II) Complexes** 400
21.2.1 Sulfur-donor ligands 400
21.2.2 Metal complexes of drugs used as ligands 404
21.2.3 Palladium(II) complexes with Schiff base ligands 405
21.2.4 Miscellaneous 406

21.3 **Anti-tumor Activity of Pd(II) Complexes** 407
21.3.1 Sulfur-donor ligands 407
21.3.2 Nitrogen and other donor atoms 410

21.4 **Concluding Remarks** 414

References 415

22 **$_{50}$Sn Tin Compounds and Their Therapeutic Potential** 421
Marcel Gielen and Edward R.T. Tiekink

22.1 **Introduction** 421

22.2 **Structures of Organotin Compounds in Solution** 422

22.3 **Anti-tumour Pre-screening** 422

22.4 **Early *In Vitro* Cytotoxicity Testing of Diorganotin Carboxylates** 423

22.5 **The Di-*n*-Butyltin Analogue of Carboplatin** 425

22.6 **Anti-tumour Potential of Triorganotin Carboxylates** 426

22.7 **Anti-tumour Screening of Organotin Derivatives of Biologically Relevant Substrates** 427

22.8 **Anti-tumour Potential of Fluorine-Substituted Organotin Carboxylates** 428

22.9 **Anti-tumour Potential of Boron-Containing Organotin Carboxylates** 428

22.10 Anti-tumour Potential of Organotin Carboxylates-Containing Polyoxaalkyl Moieties 430

22.11 Mode of Action of Cytotoxic Organotin Compounds 431

22.12 Other Therapeutic Potential of Organotin Compounds 431

22.13 Therapeutic Potential of Tin Compounds Without Tin-to-Carbon Bonds 433

22.14 Conclusions 435

Acknowledgements 435

References 435

23 $_{51}$Sb Antimony in Medicine 441
Siucheong Yan, Lan Jin and Hongzhe Sun

23.1 Introduction 441

23.2 The Chemistry of Antimony 441

23.3 Antimony in Medicine 443
23.3.1 Historic view of antimony drugs 443
23.3.2 Applications of antimony drugs as anti-leishmanial agents 444
23.3.3 Other medicinal applications 445

23.4 Pharmacology, Toxicology and Metabolism of Antimony Drugs 447
23.4.1 Pharmacology and human toxicology of antimony drugs 447
23.4.2 Pharmacokinetics studies and clinical aspect of antimony drugs 448

23.5 Possible Mechanism of Action of Antimony Drugs: Interaction of Antimony with Biologically Relevant Molecules 449

23.5.1 General hypothesis on the mechanisms of action of antimony anti-leishmanial compounds 449
23.5.2 *In vitro* and *in vivo* reduction of antimony(V) drugs 449
23.5.3 Interaction of antimony(III) compounds with thiolate molecules 450
23.5.4 Inhibition of topoisomerase I from *Leishmania donovani* and formation of DNA-protein complexes by Sb^V 453
23.5.5 Antimony-mediated DNA fragmentation, apoptosis and Ca^{2+}-related programmed cell death in *Leishmania* 454
23.5.6 Interference of the exclusive purine scavenge pathway of *Leishmania* 454
23.5.7 Modulation and increase of cellular signaling of the host macrophage as a means of intracellular *Leishmania* elimination 455

23.6 Concluding Remarks 457

Abbreviations 457

Acknowledgement 457

References 457

24 $_{75}$Re Therapeutic Rhenium Radiopharmaceuticals 463
Jonathan R. Dilworth and Paul S. Donnelly

24.1 Introduction 463

24.2 Synthetic Aspects of Rhenium Radiopharmaceuticals 466
24.2.1 Complexes of bifunctional ligands 467

24.3 The Radiopharmaceutical Chemistry of Rhenium 467
24.3.1 Complexes with oxo-cores 467
24.3.2 Complexes with cores containing metal–nitrogen multiple bonds 472
24.3.3 Complexes of the Re(I) tricarbonyl core 474

24.3.4 Organometallic approaches 479
24.3.5 Miscellaneous approaches 480

24.4 **'First-Generation' Rhenium Agents** 482
24.4.1 Bone-targeting phosphonate complexes 482
24.4.2 [Re(V)-oxo(DMSA)] 483
24.4.3 Rhenium agents for endovascular radiation therapy 484
24.4.4 Rhenium agents for radiation synovectomy 485

24.5 **Summary** 485

References 486

25 **$_{78}$Pt Platinum-Based Drugs** 489
Viktor Brabec and Jana Kasparkova

25.1 **Introduction, Anti-tumor Activity of Cisplatin** 489

25.2 **Anti-tumor Activity of Carboplatin, Oxaliplatin and Nedaplatin** 490

25.3 **Mechanism of Action of Cisplatin** 491

25.4 **Mechanism of Action of Carboplatin, Oxaliplatin and Nedaplatin** 494

25.5 **Activation of *trans* Geometry** 495

25.6 **Polynuclear Platinum Compounds** 498

25.7 **Platinum(IV) Compounds** 499

25.8 **Targeted Analogues** 500

25.9 **Anti-viral Activity** 501

25.10 **Combinations of Platinum Complexes with Other Agents** 502

25.11 **Conclusions** 502

Acknowledgements 503

References 503

26 $_{79}$Au Gold-Based Metallotherapeutics: Use and Potential 507
Soo Yei Ho and Edward R.T. Tiekink

26.1 Preamble 507

26.2 The Physical and Chemical Properties of Gold 507
26.2.1 Physical properties of the element 507
26.2.2 Chemical reactivity of gold 508
26.2.3 Oxidation states and stereochemistries of gold complexes 508

26.3 Gold in Medicine 510
26.3.1 Historical perspective 510
26.3.2 Gold therapy for rheumatoid arthritis 511

26.4 Metabolism of Gold Drugs 514
26.4.1 Biological ligand exchange 514
26.4.2 Gold in cells: The thiol-shuttle model 514
26.4.3 Cyanide metabolites 515

26.5 Pharmacological Potential of Gold Complexes 516
26.5.1 Motivation for drug development 516
26.5.2 Anti-tumour properties of gold drugs 517
26.5.3 Tetrahedral gold(I) complexes 518
26.5.4 Auranofin analogues 518
26.5.5 Gold(III) complexes 520

26.6 Other Potential Clinical Applications of Au(I) Complexes 521
26.6.1 Anti-microbial activity 521
26.6.2 Anti-malaria activity 522
26.6.3 Treatment of bronchial asthma 523
26.6.4 Anti-HIV activity and AIDS 524

26.7 Conclusions and Outlook 524

Acknowledgements 524

References 524

27 $_{83}$Bi Bismuth-Based Pharmaceuticals 529
Neil Burford and Melanie D. Eelman

27.1 Introduction 529

27.2 Bismuth-Based Therapeutics 529

27.3 Fundamental Aspects of Bismuth Chemistry and Methods of Characterization 530

27.4 Hydroxycarboxylate Complexes of Bismuth 531

27.5 Development of Bioactive Bismuth Compounds 534

27.6 Interactions of Bismuth Compounds with Biological Molecules 537

27.7 Concluding Remarks 539

References 539

28 Paramagnetic Metal Complexes as Contrast Agents for Magnetic Resonance Imaging 541
Silvio Aime, Alessandro Barge, Eliana Gianolio, Simonetta Geninatti Crich, Walter Dastrù and Fulvio Uggeri

28.1 Generalities on Magnetic Resonance Imaging (MRI) and Paramagnetic Contrast Agents 541

28.2 Determinants of the Relaxivity of Paramagnetic Metal Complexes 544

28.3 Responsive Agents 548
28.3.1 pH sensitive agents 549
28.3.2 Agents sensitive to the redox potential 551
28.3.3 Enzyme responsive agents 552

28.4 Targeting Cells with Gd(III) Chelates 554
28.5 Concluding Remarks 559
References 559

Index 561